US · Healthcare · Medical Devices
EPS came in at -0.47 against a street estimate of -0.46 — a miss of 2.2%.
Analysts rate Procept Biorobotics Corp a buy (7 buy, 4 hold, 1 sell out of 12) with an average price target of $21.64.
| Fund | Stake |
|---|---|
| BlackRock Inc | 7.62% |
| T. Rowe Price Investment Management,Inc. | 5.72% |
| BNP Paribas Investment Partners SA | 5.39% |
| Vanguard Portfolio Management, LLC | 4.23% |
| Vanguard Capital Management, LLC | 4.19% |
| Chicago Capital LLC | 3.62% |
| Mackenzie Investments | 3.00% |
| State Street Corp | 2.67% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 PROCEPT BIOROBOTICS CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue (6M 2026): $177.6 million, up 19.7% vs $148.3 million (6M 2025) • | 2026-08-05 |
| Results announced · Q3 2026 PROCEPT BIOROBOTICS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Total revenue Q2 2026: $94.5 million, up 19% year-over-year • U.S. procedures Q2 202 | 2026-08-04 |
| Shareholder vote results · Q2 2026 PROCEPT BIOROBOTICS CORPORATION — FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held June 9, 2026 • Total votes cast for director n | 2026-06-10 |
| Quarterly report · Q1 2026 PROCEPT BIOROBOTICS CORPORATION – Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Revenue: $83.1 million (Q1 2026) vs $69.2 million (Q1 2025) — growth of 20 | 2026-04-30 |
| Results announced · Q2 2026 PROCEPT BioRobotics Q1 2026 Earnings Summary HEADLINE NUMBERS • Total revenue Q1 2026: $83.1 million, up 20% year-over-year • U.S. procedures: appro | 2026-04-29 |
| Proxy statement · Q2 2026 PROCEPT BioRobotics Corporation – 2026 Proxy Summary WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1: Election of Three Class II Directors - Nominees | 2026-04-22 |
| Board / officer change · Q1 2026 PROCEPT BIOROBOTICS CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Board expansion: Board size increased from 8 to 9 members effective March 5, 2 | 2026-03-06 |
| Annual report FY2025 PROCEPT BIOROBOTICS CORPORATION – 10-K SUMMARY HEADLINE NUMBERS • Revenue for fiscal year 2025: $308.1 million (vs. $224.5 million in 2024) – 37% in | 2026-02-26 |
Readable in the app.
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Procept Biorobotics Corp — free to start.
Google PlayApp StoreData updated 2026-09-18.